Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Roivant Sciences Ltd. (ROIV : NSDQ)

• Company Description    Roivant Sciences is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients. Roivant Sciences, formerly known as Montes Archimedes Acquisition Corp., is based in NEW YORK. Number of Employees: 750

• Price / Volume Information    Yesterday's Closing Price: $22.10 Daily Weekly Monthly 20 Day Moving Average: 6,202,545 shares Shares Outstanding: 695.49 (millions) Market Capitalization: $15,370.37 (millions) Beta: 1.22 52 Week High: $22.45 52 Week Low: $8.73 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 7.49% 6.07% 12 Week 46.45% 42.26% Year To Date 86.81% 53.74%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 7th Floor 50 Broadway - LONDON,X0 SW1H 0DB GBR ph: 44-20-7400-3347 fax: - keyur.parekh@roivant.com https://roivant.com

• General Corporate Information    Officers Matthew Gline - Chief Executive Officer and Director Mayukh Sukhatme - President and Chief Investment Officer Richard Pulik - Chief Financial Officer Jennifer Humes - Chief Accounting Officer Keith Manchester - Director Peer Information Roivant Sciences Ltd. (CORR.) Roivant Sciences Ltd. (RSPI) Roivant Sciences Ltd. (CGXP) Roivant Sciences Ltd. (BGEN) Roivant Sciences Ltd. (GTBP) Roivant Sciences Ltd. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: G76279101 SIC: 2834 Fiscal Year Fiscal Year End: March Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/09/26 Share - Related Items Shares Outstanding: 695.49 Most Recent Split Date: (:1) Beta: 1.22 Market Capitalization: $15,370.37 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.38 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.61 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/09/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.17 Price/Cash Flow: - Price / Sales: 756.08 EPS Growth vs. Year Ago Period: -8.11% vs. Previous Quarter: -33.33% Sales Growth vs. Year Ago Period: -64.89% vs. Previous Quarter: -27.60% ROE 09/30/25 - -16.43 06/30/25 - -15.90 03/31/25 - -14.76 ROA 09/30/25 - -15.68 06/30/25 - -14.95 03/31/25 - -13.69 Current Ratio 09/30/25 - 33.71 06/30/25 - 40.54 03/31/25 - 33.47 Quick Ratio 09/30/25 - 33.70 06/30/25 - 40.54 03/31/25 - 33.47 Operating Margin 09/30/25 - -4,110.65 06/30/25 - -3,613.43 03/31/25 - -1,075.13 Net Margin 09/30/25 - -1,839.58 06/30/25 - -2,111.79 03/31/25 - -225.71 Pre-Tax Margin 09/30/25 - -4,259.30 06/30/25 - -4,008.14 03/31/25 - -2,346.02 Book Value 09/30/25 - 6.97 06/30/25 - 7.05 03/31/25 - 7.45 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©